#USA #New York #Pomerantz LLP #aTyr Pharma #ATYR

Investor Alert: Pomerantz Law Firm Investigates Claims for aTyr Pharma Investors

Pomerantz LLP, a distinguished law firm with a specialization in corporate and securities class litigation, has announced an investigation on behalf of investors in aTyr Pharma, Inc. (NASDAQ: ATYR). This investigation raises significant concerns regarding potential misconduct from aTyr's officers and directors,
particularly in relation to securities fraud or other unlawful business activities.

On September 15, 2025, aTyr publicly disclosed the topline results from its Phase 3 EFZO-FIT™ study involving efzofitimod in treating pulmonary sarcoidosis—a serious condition classified as a major type of interstitial lung disease. However, the company revealed that it had fallen short of meeting the primary endpoint for the trial, a disappointing outcome that sent shockwaves through the investment community.

Impact on Stock Price

In direct response to the unfavorable trial results, aTyr's stock plummeted by $5.02 a share, marking a staggering decline of approximately 83.25%, ultimately closing at only $1.01 a share on the same day. This dramatic drop illustrates the high stakes concerning the integrity of information disclosed by companies to their investors.

Pomerantz LLP is calling all investors impacted by this decline to come forward and reach out for assistance. Danielle Peyton, an attorney at the firm, can be contacted directly at [email protected] or via phone at 646-581-9980, ext. 7980, for those interested in potentially joining a class action lawsuit.

About Pomerantz LLP

Founded more than 85 years ago by Abraham L. Pomerantz, regarded as one of the pioneers in class action litigation, the firm has established itself as a leader in fighting for the rights of shareholders. Pomerantz has recovered substantial damages for class members, reflecting its commitment to holding corporations accountable for fraud and misconduct.

As the landscape for corporate governance continues to evolve, the actions of Pomerantz signal a critical lens on companies like aTyr Pharma, reinforcing the importance of transparency and accountability in corporate practices. Investors with any information that may aid this investigation are encouraged to reach out to the firm, as it seeks to protect the rights and interests of those affected by securities fraud.

Conclusion

With the ongoing investigation by Pomerantz LLP and the implications of the failed clinical trial results, investors should remain vigilant and informed. The firm's proactive approach could shed light on critical issues surrounding aTyr's operational conduct, potentially leading to significant legal actions against the company. As developments unfold, the financial community will be watching closely to see how aTyr responds and what further actions may be warranted to address these serious allegations.